Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia

Nicolas Chapuis; Laury Poulain; Rudy Birsen; Jerome Tamburini; Didier Bouscary

doi:10.3389/fonc.2019.00405

Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia

Front Oncol. 2019 May 22:9:405. doi: 10.3389/fonc.2019.00405. eCollection 2019.

Authors

Nicolas Chapuis^{1

2

3

4

5}, Laury Poulain^{1

2

3

4}, Rudy Birsen^{1

2

3

4}, Jerome Tamburini^{1

2

3

4

6}, Didier Bouscary^{1

2

3

4

6}

Affiliations

¹ INSERM U1016, Institut Cochin, Paris, France.
² CNRS UMR8104, Paris, France.
³ Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, Paris, France.
⁴ Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France.
⁵ Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Biologique, Paris, France.
⁶ Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique, Paris, France.

Abstract

Metabolic reprogramming is a common cancer cell phenotype as it sustains growth and proliferation. Targeting metabolic activities offers a wide range of therapeutic possibilities which are applicable to acute myeloid leukemia (AML). Indeed, in addition to the IDH1/2-mutated AML model which established the proof-of-concept for specifically targeting metabolic adaptations in AML, several recent reports have expanded the scope of such strategies in these diseases. This review highlights recent findings on metabolic deregulation in AML and summarizes their implications in leukemogenesis.

Keywords: acute myeloid leukemia; amino-acid; fatty acid oxidation; glycolysis; hematopoiesis; metabolism; oxidative phosphorylation; targeted therapy.

Publication types

Review